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Résumé en
anglais
First, an update of the vascular systemic and tissue renin–angiotensin–aldosterone
system is provided to explain how it is regulated at the systemic and tissue levels,
and how many angiotensin peptides and receptors can be modulated by the various
antihypertensive drugs. Second, experimental data is presented to support the
hypothesis that antihypertensive drugs that increase angiotensin II formation, such
as diuretics, AT1-receptor blockers and dihydropyridines, may have greater brain
anti-ischemic effects than antihypertensive drugs that decrease angiotensin II
formation, such as β-blockers and angiotensin-converting enzyme inhibitors, because
they increase activation of angiotensin AT2 and AT4 receptors. Indeed, these trigger
brain anti-ischemic mechanisms by favouring cerebral blood flow (angiogenesis and
recruitment of pre-existing collateral circulation, specifically in the ischemic brain
where AT2 receptors are overexpressed) or by directly increasing neuronal
resistance to anoxia. Third, we review most of the large primary and secondary
stroke prevention trials as well as the ACCESS acute stroke trial in which
antihypertensive drugs were evaluated. With the exception of the secondary stroke
prevention trial PRoFESS, most trials support the hypothesis that angiotensin II-
increasing drugs confer specific blood pressure-independent brain ischemia
protection when compared with angiotensin II-decreasing drugs or placebo. A
careful analysis of the PRoFESS trial, however, reveals study design limitations, the
main one being that diastolic BP (<80 mmHg) in the first month post-stroke may
have been too low in at least one third of the population with baseline systolic blood
pressure less than 130 mmHg, because a high dose of telmisartan was given after a
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